KATHERINE ZUNIGA: Open Payments
NPI 1982272464 · MARSHALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,140 in 53 payments from 14 companies in 2025. Trend: 2023 $1,269 · 2024 $977 · 2025 $1,140
Food & beverage: $965Consulting: $175
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $258 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $227 |
| ABBVIE INC. | 7 | $183 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Novo Nordisk Inc | 5 | $75 |
| Lilly USA, LLC | 4 | $67 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| PENTAX of America, Inc. | 1 | $38 |
| Exact Sciences Corporation | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
Products named: Kerendia, PROLIA, VRAYLAR, FARXIGA, OTEZLA, REXULTI, JARDIANCE, GEMTESA.
Industry payments across TX — which companies pay providers there.
